Elvira D’Andrea

Featured in: Favicon

Articles

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels

Feb 9, 2023 | jamanetwork.com | Elvira D’Andrea |Deborah J. Wexler |Julie M. Paik |Ethan M. Alt

Key PointsQuestion Does the effectiveness and safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) differ from that of dipeptidyl peptidase 4 inhibitors (DPP-4i) in patients with type 2 diabetes (T2D) overall and at varying baseline hemoglobin A1c (HbA1c) levels?

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.